New Diabetes Drugs: With the current epidemic of diabetes, pharmaceutical companies are discovering diabetes treatments in new drug classes; DPP-4 inhibitors, GLP-1 analogues, and SGLT2 Inhibitors are in clinical trials or waiting for FDA approval.

 GAD-Alum
 Galvus (Vildagliptin)
 Janumet (Sitigliptin/metformin)
 Liraglutide
 Qnexa
 SGLT2 Inhibitors
 Symlin (Pramlintide)
 XOMA 052